Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 September 2022 | Story Jóhann Thormählen | Photo iStock
Cervical cancer awareness ribbon
Cervical Cancer Awareness Month is observed in September in South Africa to encourage women to go for screening to prevent it.

Cervical cancer is the second most common cancer among women in South Africa, and many die from it each year – but it can be prevented.

According to Dr Arina Meyer, medical practitioner in Kovsie Health at the University of the Free State, this is one of the reasons why it is important to be informed, take precautions, and raise awareness about the disease.

Cervical Cancer Awareness Month is observed in September in South Africa with the aim of encouraging women to go for screening to prevent it.

Although medical statistics paint a bleak picture, Meyer says there is hope. “It is important to know that cervical cancer can be prevented. And when it is diagnosed early, it can be treated.”

Statistics and causes

According to her, figures show the occurrence of cervical cancer to be between 22,8 and 27 per 100 000 women in South Africa. 

“More than 5 700 new cases are reported each year, as well as more than 3 000 deaths. Cervical cancer is the second most common cancer – after skin cancer – in South Africa.”

Meyer says when one look at these numbers, it is important to commemorate Cervical Cancer Awareness Month, as women need to be informed about their annual check-up, possible symptoms, and signs of the cancer.

Most cervical cancers are caused by the human papillomavirus (HPV), which is transmitted through sexual contact. Therefore, the HPV is seen as a sexually transmitted disease.

“There are different types of HPV. Some cause cervical cancer and other genital warts. One can develop one or both conditions, depending on the type of virus you have,” says Meyer.

Prevention and reducing the risk

According to her, preventative action is the best method. Going for a cervical screening every year when you become sexually active, such as a Pap smear or Pap test, will help in the early detection and removal of abnormal cells.

There is also a vaccine for protection against HPV, which is available from the age of nine. Meyer says there are two vaccines in South Africa.

“By getting the vaccine early, before any sexual activity, the spread of HPV – and therefore cervical cancer – can be prevented. Up to 90% of cancers can be prevented.
“Unfortunately, if someone has already been infected by the HPV, it cannot be treated by the vaccine.”

The UFS medical practitioner says the best ways to reduce the risk of cervical cancer are to go for an annual Pap smear, a follow-up after an abnormal test result, the vaccine, safe sex, and to stop smoking.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept